# Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

> **NCT03972046** · PHASE2 · WITHDRAWN · sponsor: **TriHealth Inc.**

## Conditions studied

- Melanoma (Skin)
- Melanoma Stage IIIb-IVM1a
- Metastasis Skin
- Tumor Skin
- BRAF Gene Mutation

## Interventions

- **DRUG:** Talimogene laherparepvec (T-Vec)
- **DRUG:** Dabrafenib (BRAF Inhibitor)
- **DRUG:** Trametinib (MEK Inhibitor)

## Key facts

- **NCT ID:** NCT03972046
- **Lead sponsor:** TriHealth Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-24
- **Primary completion:** 2020-02-03
- **Final completion:** 2020-02-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Principal investigator leaving study site; no replacement PI will be sought
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972046, "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03972046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*